

ACTIVELY ENROLLING TRIALS: JBN Medical Diagnostic Services Inc.

More information regarding these and other clinical trials can be found at www.clinicaltrials.gov

ALZHEIMER'S DISEASE

Moderate Alzheimers Disease: BP28248 MAYFLOWER Road:

This phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4602522 in patients with moderate severity Alzheimer disease. Patients who are taking background therapy of donepezil (Aricept) or rivastigmine (Exelon patch) for at least 6 months before baseline will be randomized to receive either one of two doses of RO4602522 or placebo for 12 months.

CARDIOVASCULAR EVENTS/MYOCARDIAL INFARCTION

PEGASUS : This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

CHOLESTEROL

LTS11717 ODYSSEY: Long-term safety and tolerability of sar236553 (regn727) versus placebo on top of lipid-modifying therapy in high cardiovascular risk patients with hypercholesterolemia (odyssey long term)

CORONARY ARTERY DISEASE

SIGNIFY: To evaluate the effect of heart rate reduction with ivabradine in the reduction of cardiovascular outcomes in patients with stable coronary artery disease. Medication provided. [more info](#)

DIABETES:

NN2211-3917: The effect of liraglutide versus placebo when added to basal insulin (lantus or levemir) analogues with or without metformin in subjects with type 2 diabetes

REWIND : The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.

Want to find out more? Our Coordinators will gladly assist you with any questions. [Email](#) or Contact Us at 905.331.3981.

[Back to JBN Medical](#)